vs
Protalix BioTherapeutics, Inc.（PLX）与TECHPRECISION CORP（TPCS）财务数据对比。点击上方公司名可切换其他公司
Protalix BioTherapeutics, Inc.的季度营收约是TECHPRECISION CORP的1.3倍（$9.1M vs $7.1M），TECHPRECISION CORP净利率更高（-20.8% vs -60.3%，领先39.6%），TECHPRECISION CORP同比增速更快（-6.9% vs -49.9%），Protalix BioTherapeutics, Inc.自由现金流更多（$1.6M vs $-827.0K），过去两年Protalix BioTherapeutics, Inc.的营收复合增速更高（-6.7% vs -9.2%）
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
TechPrecision Corp是一家专业生产定制高精度金属部件与集成系统的制造商，服务航空航天、国防、医疗科技、可再生能源等核心领域，为欧美客户提供符合严苛行业标准的关键任务零部件。
PLX vs TPCS — 直观对比
营收规模更大
PLX
是对方的1.3倍
$7.1M
营收增速更快
TPCS
高出43.0%
-49.9%
净利率更高
TPCS
高出39.6%
-60.3%
自由现金流更多
PLX
多$2.5M
$-827.0K
两年增速更快
PLX
近两年复合增速
-9.2%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $9.1M | $7.1M |
| 净利润 | $-5.5M | $-1.5M |
| 毛利率 | 49.4% | 5.4% |
| 营业利润率 | -51.1% | -19.1% |
| 净利率 | -60.3% | -20.8% |
| 营收同比 | -49.9% | -6.9% |
| 净利润同比 | -184.8% | -84.4% |
| 每股收益（稀释后） | $-0.06 | $-0.15 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PLXTPCS
| Q4 25 | $9.1M | $7.1M | ||
| Q3 25 | $17.9M | $9.1M | ||
| Q2 25 | $15.7M | $7.4M | ||
| Q1 25 | $10.1M | $9.5M | ||
| Q4 24 | $18.2M | $7.6M | ||
| Q3 24 | $18.0M | $8.9M | ||
| Q2 24 | $13.5M | $8.0M | ||
| Q1 24 | — | $8.6M |
净利润PLXTPCS
| Q4 25 | $-5.5M | $-1.5M | ||
| Q3 25 | $2.4M | $825.0K | ||
| Q2 25 | $164.0K | $-597.0K | ||
| Q1 25 | $-3.6M | $112.0K | ||
| Q4 24 | $6.5M | $-799.0K | ||
| Q3 24 | $3.2M | $-601.0K | ||
| Q2 24 | $-2.2M | $-1.5M | ||
| Q1 24 | — | $-5.1M |
毛利率PLXTPCS
| Q4 25 | 49.4% | 5.4% | ||
| Q3 25 | 53.4% | 27.1% | ||
| Q2 25 | 62.5% | 14.0% | ||
| Q1 25 | 19.1% | 22.0% | ||
| Q4 24 | 78.7% | 13.0% | ||
| Q3 24 | 53.4% | 11.3% | ||
| Q2 24 | 29.8% | 3.0% | ||
| Q1 24 | — | 14.3% |
营业利润率PLXTPCS
| Q4 25 | -51.1% | -19.1% | ||
| Q3 25 | 11.9% | 10.4% | ||
| Q2 25 | 7.5% | -6.3% | ||
| Q1 25 | -41.0% | 3.9% | ||
| Q4 24 | 39.6% | -9.1% | ||
| Q3 24 | 22.2% | -5.5% | ||
| Q2 24 | -18.0% | -16.8% | ||
| Q1 24 | — | -28.6% |
净利率PLXTPCS
| Q4 25 | -60.3% | -20.8% | ||
| Q3 25 | 13.2% | 9.1% | ||
| Q2 25 | 1.0% | -8.1% | ||
| Q1 25 | -35.8% | 1.2% | ||
| Q4 24 | 35.6% | -10.5% | ||
| Q3 24 | 18.0% | -6.7% | ||
| Q2 24 | -16.4% | -18.3% | ||
| Q1 24 | — | -59.5% |
每股收益（稀释后）PLXTPCS
| Q4 25 | $-0.06 | $-0.15 | ||
| Q3 25 | $0.03 | $0.08 | ||
| Q2 25 | $0.00 | $-0.06 | ||
| Q1 25 | $-0.05 | $0.01 | ||
| Q4 24 | $0.10 | $-0.08 | ||
| Q3 24 | $0.03 | $-0.06 | ||
| Q2 24 | $-0.03 | $-0.16 | ||
| Q1 24 | — | $-0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $14.7M | $50.0K |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $48.2M | $8.0M |
| 总资产 | $82.3M | $32.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PLXTPCS
| Q4 25 | $14.7M | $50.0K | ||
| Q3 25 | $13.6M | $220.0K | ||
| Q2 25 | $17.9M | $143.0K | ||
| Q1 25 | $19.5M | $195.0K | ||
| Q4 24 | $19.8M | $165.0K | ||
| Q3 24 | $27.4M | $132.0K | ||
| Q2 24 | $23.4M | $44.8K | ||
| Q1 24 | — | $138.0K |
总债务PLXTPCS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $3.0K | ||
| Q4 24 | — | $19.0K | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益PLXTPCS
| Q4 25 | $48.2M | $8.0M | ||
| Q3 25 | $52.9M | $9.1M | ||
| Q2 25 | $49.9M | $8.2M | ||
| Q1 25 | $45.2M | $8.7M | ||
| Q4 24 | $43.2M | $8.1M | ||
| Q3 24 | $32.4M | $8.9M | ||
| Q2 24 | $28.6M | $7.9M | ||
| Q1 24 | — | $7.8M |
总资产PLXTPCS
| Q4 25 | $82.3M | $32.8M | ||
| Q3 25 | $82.3M | $33.8M | ||
| Q2 25 | $78.5M | $32.1M | ||
| Q1 25 | $73.9M | $33.5M | ||
| Q4 24 | $73.4M | $32.2M | ||
| Q3 24 | $61.6M | $35.0M | ||
| Q2 24 | $91.5M | $35.7M | ||
| Q1 24 | — | $34.7M |
负债/权益比PLXTPCS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.0M | $183.0K |
| 自由现金流经营现金流 - 资本支出 | $1.6M | $-827.0K |
| 自由现金流率自由现金流/营收 | 17.8% | -11.7% |
| 资本支出强度资本支出/营收 | 4.4% | 14.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-13.6M | $-4.4M |
8季度趋势，按日历期对齐
经营现金流PLXTPCS
| Q4 25 | $2.0M | $183.0K | ||
| Q3 25 | $-3.7M | $-1.1M | ||
| Q2 25 | $-5.2M | $646.0K | ||
| Q1 25 | $-5.1M | $396.0K | ||
| Q4 24 | $4.0M | $-570.0K | ||
| Q3 24 | $4.1M | $-532.0K | ||
| Q2 24 | $-3.6M | $107.0K | ||
| Q1 24 | — | $-452.0K |
自由现金流PLXTPCS
| Q4 25 | $1.6M | $-827.0K | ||
| Q3 25 | $-4.2M | $-2.1M | ||
| Q2 25 | $-5.7M | $-604.0K | ||
| Q1 25 | $-5.4M | $-930.0K | ||
| Q4 24 | $3.6M | $-1.7M | ||
| Q3 24 | $4.0M | $-2.0M | ||
| Q2 24 | $-3.8M | $-94.0K | ||
| Q1 24 | — | $-900.0K |
自由现金流率PLXTPCS
| Q4 25 | 17.8% | -11.7% | ||
| Q3 25 | -23.7% | -22.9% | ||
| Q2 25 | -36.2% | -8.2% | ||
| Q1 25 | -53.0% | -9.8% | ||
| Q4 24 | 19.6% | -22.9% | ||
| Q3 24 | 22.4% | -21.8% | ||
| Q2 24 | -28.1% | -1.2% | ||
| Q1 24 | — | -10.5% |
资本支出强度PLXTPCS
| Q4 25 | 4.4% | 14.2% | ||
| Q3 25 | 2.8% | 11.0% | ||
| Q2 25 | 2.8% | 16.9% | ||
| Q1 25 | 3.0% | 14.0% | ||
| Q4 24 | 2.3% | 15.4% | ||
| Q3 24 | 0.5% | 15.9% | ||
| Q2 24 | 1.3% | 2.5% | ||
| Q1 24 | — | 5.2% |
现金转化率PLXTPCS
| Q4 25 | — | — | ||
| Q3 25 | -1.58× | -1.31× | ||
| Q2 25 | -31.91× | — | ||
| Q1 25 | — | 3.54× | ||
| Q4 24 | 0.61× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
TPCS
| Defense | $6.7M | 94% |
| Other | $410.0K | 6% |
